# Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

> **NCT02607423** · PHASE2 · WITHDRAWN · sponsor: **ECOG-ACRIN Cancer Research Group**

## Conditions studied

- Stage IIIA Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Cisplatin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Docetaxel
- **RADIATION:** Fludeoxyglucose F-18
- **DRUG:** Gemcitabine Hydrochloride
- **DRUG:** Pemetrexed Disodium
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT02607423
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-11-19
- **Primary completion:** 2017-01-31
- **Final completion:** 2017-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study failed to meet its accrual targets.
- **Last updated:** 2023-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02607423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02607423, "Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02607423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*